Provention raises $28.4M in series A

Autoimmune and inflammatory disease prevention and interception play Provention Bio Inc. (Lebanon, N.J.) said it raised $28.4 million in a series A round from the Johnson & Johnson Innovation-JJDC Inc. arm of Johnson & Johnson (NYSE:JNJ), the

Read the full 372 word article

User Sign In